There are differences between familial and idiopathic pulmonary fibrosis in terms of cluster of differentiation 20 and CD3 expression.
WALTHAM, MA - April 23, 2026 - - KACTUS has published a technical framework for engineering 2+1 and trispecific T-cell engager therapeutics, addressing structural scaffold challenges for drug ...
New approval allows teplizumab use in children as young as 1 year, significantly delaying stage 3 type 1 diabetes onset and ...
The U.S. Food and Drug Administration has broadened approval of Teplizumab-developed by Sanofi-to include children as young ...
US FDA approves Sanofi's Tzield to delay the onset of stage 3 type 1 diabetes in young children: Paris Friday, April 24, 2026, 11:00 Hrs [IST] The US Food and Drug Administration ...
Scientific Advisory Board (SAB) includes experts in the development and approved T-cell engager therapies, supporting CAPTN-3’s advancement toward clinical-stage immunotherapy d ...
At AACR 2026, scientists showcased advances in radiotherapeutics, antibody-drug conjugates, T cell engagers, and ...
Health and Me on MSN
Type 1 diabetes: US FDA expands Sanofi’s Tzield to treat children aged 1
Tzield is a CD3-directed monoclonal antibody drug that was first approved in the US in November 2022 to delay the onset of ...
The rheumatoid arthritis clinical trial analysis report delivers important insights into ongoing research of 80+ pipeline ...
Researchers at UNSW Sydney have pinpointed genes that may play a causal role in vascular dementia, offering promising leads for drug development. The study used Mendelian randomization to analyze over ...
Poseidon Bio has developed an innovative modular technology platform based on an engineered human protein scaffold that can generate TCEs with a novel geometry to overcome the problems of current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results